Filing Details
- Accession Number:
- 0001209191-23-002895
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-10 20:30:16
- Reporting Period:
- 2023-01-06
- Accepted Time:
- 2023-01-10 20:30:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1891900 | Brendan Teehan | C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130 | Evp, Coo, Head Of Commercial | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-06 | 1,286 | $0.00 | 5,081 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-09 | 532 | $17.13 | 4,549 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2022-01-06 | 1,286 | $0.00 | 1,286 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2023-01-06 | 1,286 | $0.00 | 1,286 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 2,573 | No | 4 | M | Direct | ||
| 1,287 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.
- Includes 358 shares of the Issuer's common stock acquired by the reporting person on May 16, 2022 pursuant to an employee stock purchase program.
- The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.13 to $17.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- This restricted stock units is being re-reported solely to correct vesting terms on the Form 4 filed on January 10, 2022, which erroneously indicated that the restricted stock units vest in four equal annual installments beginning January 6, 2021. The correct vesting is one-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.
- One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024.
Billionaire Hedge Funds
